Physician profile
Mark Vollenweider
NPI 1356331698
$36,850.57
in general payments reported to CMS, 2019-2025
23 companies · $12K in 2025
The $12K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,893 · 2020: $338 · 2021: $948 · 2022: $1,017 · 2023: $1,335 · 2024: $15K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $4,062 · Food and Beverage: $2,127 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,450.00 |
| Travel and Lodging | $4,061.60 |
| Food and Beverage | $2,126.96 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $28,094.95 | 2021-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Ethicon INC. | $5,214.00 | 2019-2021 | |
| Intuitive Surgical, INC. | $1,707.67 | 2021-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals Lp | $311.10 | 2019-2024 | Imfinzi |
| Glaxosmithkline, LLC. | $288.63 | 2019-2021 | |
| Galvanize Therapeutics, INC | $211.20 | 2025 | Aliya System |
| Sunovion Pharmaceuticals INC. | $196.49 | 2019 | |
| Merck Sharp & Dohme LLC | $174.55 | 2019-2023 | Keytruda |
| Genzyme Corporation | $126.78 | 2019-2020 | |
| Janssen Biotech, INC. | $101.94 | 2023 | Rybrevant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.99 | 2019-2021 | |
| Veran Medical Technologies, INC. | $73.61 | 2021 | |
| Mallinckrodt Enterprises LLC | $50.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $46.42 | 2019-2021 | |
| Insmed, INC. | $32.48 | 2022-2024 | Arikayce |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $19.94 | 2019 | |
| Auris Health, INC. | $19.57 | 2019 | |
| Mylan Specialty L.P. | $18.38 | 2019 | |
| Electromed, INC. | $16.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.48 | 2019 | |
| Spr Therapeutics, INC | $14.47 | 2021 | |
| Fisher & Paykel Healthcare INC | $13.04 | 2019 | |
| Genentech USA, INC. | $12.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vollenweider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.